Test your knowledge on second-line treatment and side-effect management in mHER2+ breast cancer

Which of the following are adverse events associated with trastuzumab deruxtecan in the DESTINY-Breast01 and 03 clinical trials?
Nausea
Interstitial lung disease (ILD)/pneumonitis
Vomiting
All of the above
If a patient experiences asymptomatic grade 1 interstitial lung disease (ILD) associated with trastuzumab deruxtecan (T-DXd), which of the following actions should be taken, according to treatment guidelines?
Permanently discontinue T-DXd
Dose reduce T-DXd
Hold T-DXd and initiate prednisone
Switch from T-DXd to trastuzumab emtansine (T-DM1)
Which of the following actions should be taken for a patient initiating trastuzumab deruxtecan (T-DXd) who has moderate hepatic impairment (>1.5 to 3.0 mg/dL)?
Monitor closely
Immediately reduce T-DXd dose
Do not start T-DXd treatment
Hold T-DXd and check liver function again in 6 weeks
{"name":"Test your knowledge on second-line treatment and side-effect management in mHER2+ breast cancer", "url":"https://www.poll-maker.com/QVUQMYLIX","txt":"Which of the following are adverse events associated with trastuzumab deruxtecan in the DESTINY-Breast01 and 03 clinical trials?, If a patient experiences asymptomatic grade 1 interstitial lung disease (ILD) associated with trastuzumab deruxtecan (T-DXd), which of the following actions should be taken, according to treatment guidelines?, Which of the following actions should be taken for a patient initiating trastuzumab deruxtecan (T-DXd) who has moderate hepatic impairment (>1.5 to 3.0 mg\/dL)?","img":"https://www.poll-maker.com/3012/images/ogquiz.png"}
Tools: Poll Maker | Quiz Maker | Super Surveys